Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism

Dominique Sternadt, Diego A. Pereira-Martins, Douglas RA Silveira, Isabel Weinhaeuser, Ming Yang, Prodromos Chatzikyriakou, Pilar Casares Alaez, Ayşegül Erdem, Lieve Oudejans, Shanna Hogeling, Emanuele Ammatuna, Gerwin Huls, Christian Frezza, Lynn Quek, Jan Jacob Schuringa

Blood (2024) 144 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2024-208239

Published: 2024

Journal Articles

The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation

César Alexander Ortiz Rojas, Diego A. Pereira-Martins, Carol Thomé, Germano Ferreira, Thiago Mantello Bianco, Isabel Weinhäuser, Cleide Lúcia Araújo Silva, Lorena Pontes, Vitor Faça, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M. Rego

Blood (2024) 144 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2024-205613

Published: 2024

Journal Articles

The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b

Diego A. Pereira-Martins, Vincent Van Den Boom, Isabel Weinhaeuser, Nisha van der Meer, Prodromos Chatzikyriakou, Noortje van Dijk, Xuesen Zheng, Lucio H Pinheiro, Douglas RA Silveira, Thiago Mantello Bianco, César Alexander Ortiz Rojas, Eduardo M. Rego, Stuart A Rushworth, Antonio R. Lucena-Araujo, Lynn Quek, Gerwin Huls, Jan Jacob Schuringa

Blood (2024) 144 (Supplement 1): 4321.

https://doi.org/10.1182/blood-2024-207421

Published: 2024

Journal Articles

Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors

Manuela Albuquerque De Melo, Diego A. Pereira-Martins, Brunno Gilberto Santos Macedo, Livia Bassani Lins de Miranda, Priscila Santos Scheucher, Isabel Weinhäuser, Gerwin Huls, Jan Jacob Schuringa, João Agostinho Machado-Neto, Fabiola Traina

Blood (2024) 144 (Supplement 1): 2752.

https://doi.org/10.1182/blood-2024-203390

Published: 2024

Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Blood (2024) 144 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2024-199211

Published: 2024

Journal Articles

Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML

Lucio Henrique Pinheiro, Isabel Weinhäuser, Diego A. Pereira-Martins, Luise Araujo De Albuquerque Simoes, Matthew Markham, Lynn Quek, Gerwin Huls, Jan Jacob Schuringa, Stuart A Rushworth, Eduardo M. Rego

Blood (2024) 144 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2024-208800

Published: 2024

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Mirian Brink, Arie C. van der Spek, Koen de Heer, Sabina Kersting, Lidwine W. Tick, Hanneke M. van der Straaten, Rogier Mous, Mark-David Levin, Doreen te Raa, Michel van Gelder, Jeanette K. Doorduijn, Arnon P. Kater, Gerwin Huls, Mar Bellido

Blood (2022) 140 (Supplement 1): 3788–3789.

https://doi.org/10.1182/blood-2022-168849

Published: 2022

Journal Articles

Dietary methionine starvation impairs acute myeloid leukemia progression

Blood (2022) 140 (19): 2037–2052.

https://doi.org/10.1182/blood.2022017575

Published: 2022

Includes: Supplemental data

Journal Articles

COPD makes CHIP less indeterminate

Gerwin Huls

Blood (2022) 139 (3): 310–311.

https://doi.org/10.1182/blood.2021013966

Published: 2022

Journal Articles

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Ewa Cendrowicz, PhD, Lisa Jacob, Shirley Greenwald, Ami Tamir, Yosi Gozlan, Gerwin Huls, MD PhD, Adam Foley-Comer, Yaron Pereg, Ayelet Chajut, Amnon Peled, PhD, Edwin Bremer, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140280

Published: 2020

Journal Articles

The long road: improving outcome in elderly “unfit” AML?

Bob Löwenberg, Gerwin Huls

Blood (2020) 135 (24): 2114–2115.

https://doi.org/10.1182/blood.2020005651

Published: 2020

Journal Articles

Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals

Isabelle A. van Zeventer, Aniek O. de Graaf, Hanneke J. C. M. Wouters, Bert A. van der Reijden, Melanie M. van der Klauw, Theo de Witte, Marianne A. Jonker, Luca Malcovati, Joop H. Jansen, Gerwin Huls

Blood (2020) 135 (14): 1161–1170.

https://doi.org/10.1182/blood.2019004362

Published: 2020

Includes: Supplemental data

Journal Articles

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Blood (2019) 134 (Supplement_1): 5144.

https://doi.org/10.1182/blood-2019-127138

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Blood (2018) 132 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2018-99-112615

Published: 2018

Journal Articles

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Tom Van Meerten, Renee Bouwstra, Bsc, Yuan He, PhD, de Boer Janneke, Bsc, Hilde Kooistra, MD PhD, Rudolf Fehrmann, MD PhD, Emanuele Ammatuna, MD PhD, Gerwin Huls, MD PhD, Edwin Bremer, PhD

Blood (2018) 132 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2018-99-114561

Published: 2018

NARROW

DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism

The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation

The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b

Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Dietary methionine starvation impairs acute myeloid leukemia progression

COPD makes CHIP less indeterminate

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

The long road: improving outcome in elderly “unfit” AML?

Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only